# A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

> **NCT03024580** · PHASE2 · UNKNOWN · sponsor: **Instituto Nacional de Cancer, Brazil** · enrollment: 20 (estimated)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Megestrol Acetate 160Mg Tablet
- **DRUG:** Anastrozole 1Mg Tablet
- **DRUG:** Letrozole 2.5Mg Tablet
- **DRUG:** Exemestane 25 MG
- **DRUG:** Tamoxifen 20Mg Tablet
- **DRUG:** Fulvestrant 50Mg Solution for Injection

## Key facts

- **NCT ID:** NCT03024580
- **Lead sponsor:** Instituto Nacional de Cancer, Brazil
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-06
- **Primary completion:** 2020-03
- **Final completion:** 2020-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024580, "A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03024580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*